Biotech M&A Happenings - Roche Acquires Telavant for $7.1B; Bristol Acquires Mirati for $4.8B

Muni Investing - Even if Rates Stay Neutral, Muni Coupons Have Positive Yields. Attractive Indeed

Uncertainty Rising. Volatility Falling. Markets Depressing. A Look at September.

Down Down Down Goes Biotech - But Insiders Are Optimistic and Buying

M&A Picking Up: Bristol Myers and Eli Lilly on the Offensive

M&A Continues - Eli Lilly Ponies Up $1.4B for Point Biopharma

The Highs and Lows of Biotech Investing Continue Apace - SLNO Up 500%+

What Happens to Stock and Bond Correlations During Inflationary Periods?

Let's Look at Commercial and Residential Real Estate

Lots of Rough News but Not Time to Walk or Run Away

Doom Loop in Commercial Real Estate Does Not Mean Investors Should Stay Away...Or Does It???

Continue to Keep an Eye on the VIX - A Spring Coil Loading

Is Biotech Dependent on M&A For Returns Now?

Biotech & MedTech Capital Markets Update - 120 Biotech Transactions YTD

Record Biotech Financing Has Increased Competition but Not Necessarily Winners

A Hurricane Can Be Just a Press Release Away - When the FDA Comes, the Wind Blows

Is All-Weather a Reasonable Set-Up for a Portfolio? What Is All-Weather?